Abstract Library

#2271 Effects of Multi-Receptor Targeting Drugs in Neuroendocrine Tumors Using 3D Cell Culture

Introduction: Symptom control in functioning neuroendocrine tumors(NETs) may be difficult in some cases, thus, new therapeutic options, including multi-receptor targeting drugs are required.

Conference: 15th Annual ENETSConcerence (2018)

Presenting Author: Herrera-Martínez A

Authors: Herrera-Martínez A, Van Dungen R, Van Koetsveld P, Dogan-Oruc F, Culler M,

Keywords: NETs, somatostatin receptors, dopamine receptors, multi-receptor targeting drugs, hormone secretion,

#1581 Evaluation of Somatostatin and Dopamine Receptor Subtype 2 Expression in Pancreatic Neuroendocrine Neoplasms

Introduction: Although somatostatin receptor subtype 2 (SSTR2) and dopamine type 2 receptor (D2R) are reported to be expressed in neuroendocrine neoplasms (NEN), there is a lack of data from studies on a large number of patients with pancreatic NEN.

Conference: 14th Annual ENETSConcerence (2017)

Presenting Author: Lee L

Authors: Lee L, Ito T, Kawabe K, Otsuka T, Nakamura M,

Keywords: Somatostatin receptor, dopamine receptor, SSTR2, D2R,

#532 Effect of the Combined Administration of mTOR Inhibitor and Dopamine or Somatostatin Analogues in a Human Bronchial Neuroendocrine Cell Line

Introduction: The mTOR inhibitor rapamycin (RAP) has been considered an anticancer agent. The role of dopamine and somatostatin in controlling cell secretion and proliferation in neuroendocrine tumors (NETs) is still unclear.

Conference: 9th Annual ENETSConcerence (2012)

Presenting Author:

Authors: Pivonello R, Sarnataro M, Cariati F, Pivonello C, Colao A,

Keywords: neuroendocrine tumor, mTOR inhibitors, dopamine agonists, somatostatin analogues,

#245 Expression of Somatostatin Receptors and Dopamine 2 Receptor in Lung Carcinoids as a Possible Biotherapy Target

Introduction: Expression of somatostatin receptors (SSTRs) and dopamine 2 receptor (D2R) in neuroendocrine tumors is of clinical importance, as somatostatin analogues and dopamine agonists are used in biotherapy.

Conference: 8th Annual ENETSConcerence (2011)

Presenting Author:

Authors: Kanakis G, Grimelius L, Trigidou R, Kaltsas G, Tsolakis A,

Keywords: somatostatin receptor subtypes, dopamine receptor 2, lung carcinoids,